Xiamen Cancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
Breast. 2014 Feb;23(1):88-93. doi: 10.1016/j.breast.2013.11.003. Epub 2013 Dec 2.
The prognostic significance of preoperative carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels in breast cancer is controversial. This study evaluated the prognostic value of preoperative serum CEA and CA15-3 levels in Chinese breast cancer patients. A total of 470 patients with breast cancer had preoperative CEA and CA15-3 concentrations measured. The relationships between preoperative concentration and clinicopathological factors and outcomes were determined. CEA and CA15-3 levels were increased in 34 (7.2%) and 58 (12.3%) patients, respectively. Elevations of serum CEA and CA-15-3 levels correlated with the primary tumor size and axillary lymph node status. CEA levels were lower in patients with triple-negative breast cancer than in those with other subtypes (P = 0.002). The 5-year distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) of CEA-negative vs. CEA-positive patients were 84.1% vs. 54.5% (P < 0.001), 82.7% vs. 54.8% (P < 0.001), and 89.7% vs. 78.5% (P = 0.007), respectively. The 5-year DMFS, DFS, and OS of CA15-3-negative vs. CA15-3-positive patients were 84.0% vs. 69.6% (P = 0.002), 83.0% vs. 66.2% (P < 0.001), 90.9% vs. 74.2% (P = 0.005), respectively. Multivariate analysis of prognosis indicated that CEA and CA15-3 levels were independent prognostic factors for DMFS (P = 0.021) and DFS (P = 0.032), and DFS (P = 0.014) and OS (P = 0.032), respectively. Serum levels of CEA and CA15-3 may differ in breast cancer molecular subtypes and preoperative levels of CEA and CA15-3 have a significant effect on prognosis in Chinese women with breast cancer.
术前癌胚抗原(CEA)和肿瘤抗原 15-3(CA15-3)水平对乳腺癌的预后意义存在争议。本研究评估了术前血清 CEA 和 CA15-3 水平对中国乳腺癌患者的预后价值。470 例乳腺癌患者术前检测 CEA 和 CA15-3 浓度。确定术前浓度与临床病理因素和结果之间的关系。34 例(7.2%)和 58 例(12.3%)患者血清 CEA 和 CA15-3 水平升高。血清 CEA 和 CA-15-3 水平升高与原发肿瘤大小和腋窝淋巴结状态相关。三阴性乳腺癌患者的 CEA 水平低于其他亚型(P=0.002)。CEA 阴性患者的 5 年远处无转移生存(DMFS)、无病生存(DFS)和总生存(OS)分别为 84.1%和 54.5%(P<0.001),82.7%和 54.8%(P<0.001),89.7%和 78.5%(P=0.007)。CA15-3 阴性患者的 5 年 DMFS、DFS 和 OS 分别为 84.0%和 69.6%(P=0.002),83.0%和 66.2%(P<0.001),90.9%和 74.2%(P=0.005)。预后的多因素分析表明,CEA 和 CA15-3 水平是 DMFS(P=0.021)和 DFS(P=0.032)的独立预后因素,DFS(P=0.014)和 OS(P=0.032)。乳腺癌分子亚型的血清 CEA 和 CA15-3 水平可能不同,术前 CEA 和 CA15-3 水平对中国乳腺癌女性的预后有显著影响。